We are live on ! Find out more
MDNA

Medicenna Therapeutics Corp. Common Shares

Delisted

MDNA was delisted on the 1st of November, 2023.

31 hedge funds and large institutions have $22.9M invested in Medicenna Therapeutics Corp. Common Shares in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

111% more capital invested

Capital invested by funds: $10.8M → $22.9M (+$12.1M)

48% more funds holding

Funds holding: 2131 (+10)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

Holders
31
Holders Change
+10
Holders Change %
+47.62%
% of All Funds
0.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
5
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AIC
1
AWM Investment Company
New York
$4.07M
BOTOTLSJU
2
Board of Trustees of The Leland Stanford Junior University
California
$3.91M +$3.92M +962,932 New
ACM
3
AIGH Capital Management
Maryland
$3.43M +$3.42M +840,000 New
Verition Fund Management
4
Verition Fund Management
Connecticut
$2.2M -$2.44K -600 -0.1%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$2.15M +$2.16M +529,325 New
IIM
6
Intact Investment Management
Quebec, Canada
$1.96M +$1.57M +385,600 New
WVP
7
Worth Venture Partners
New Jersey
$807K +$806K +197,900 New
MS
8
Maven Securities
Jersey
$749K +$765K +187,789 New
Renaissance Technologies
9
Renaissance Technologies
New York
$574K +$43.6K +10,700 +8%
Millennium Management
10
Millennium Management
New York
$500K +$499K +122,488 New
SCM
11
Silverarc Capital Management
Massachusetts
$439K
TAM
12
Tocqueville Asset Management
New York
$378K
Marshall Wace
13
Marshall Wace
United Kingdom
$328K +$327K +80,401 New
Morgan Stanley
14
Morgan Stanley
New York
$276K +$236K +57,868 +595%
RG
15
Rathbones Group
United Kingdom
$163K
Creative Planning
16
Creative Planning
Kansas
$159K
Goldman Sachs
17
Goldman Sachs
New York
$151K +$150K +36,902 New
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$114K +$113K +27,823 New
MCWS
19
McKinley Carter Wealth Services
West Virginia
$102K
PFGIA
20
Patriot Financial Group Insurance Agency
Massachusetts
$84K
Geode Capital Management
21
Geode Capital Management
Massachusetts
$80K +$80.5K +19,762 New
MWNA
22
Marshall Wace North America
New York
$79K +$78.6K +19,300 New
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$47K -$48.9K -11,999 -51%
JP Morgan Chase
24
JP Morgan Chase
New York
$38K +$21.7K +5,333 +131%
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$36K +$6.75K +1,657 +23%

MDNA Hedge Fund Activity: Q1 2021 in Review

31 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2021, worth a combined $22.9M — up 111% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new MDNA positions and 3 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Board of Trustees of The Leland Stanford Junior University, opening a new position worth an estimated $3.92M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $874K sold.

  • 31 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2021, up from 21 in Q4 2020.
  • Funds reported $22.9M of Medicenna Therapeutics Corp. Common Shares stock for Q1 2021, up 111% quarter-over-quarter.
  • 13 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2021 and 3 closed out, a net change of +10 holders.
  • The largest Medicenna Therapeutics Corp. Common Shares buyer in Q1 2021 was Board of Trustees of The Leland Stanford Junior University, an estimated $3.92M added.
  • The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2021 was Soleus Capital Management, an estimated $874K sold.

Based on aggregated 13F filings for Q1 2021.